Alliance Global Partners analyst James Molloy reiterated a Buy rating on GeoVax Labs (GOVX – Research Report) today and set a price target of ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent 09.04.2025 / 15:07 CET/CEST The issuer is solely responsible ...

Continues to Strengthen Its Pandemic Preparedness and Biodefense Vaccine Portfolio ATLANTA, GA - April 9, 2025 (NEWMEDIAWIRE) ...

Investment analysts at Roth Capital issued their FY2029 EPS estimates for shares of GeoVax Labs in a research note issued on ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

— We have everything you need: full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q4 2024 Earnings Call Transcript March 27, 2025 GeoVax Labs, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.79. Operator ...

Good afternoon. And welcome everyone to the GeoVax Fourth Quarter Full Year 2024 Corporate Update Call. My name is Michelle and I will facilitate today’s call. With me are David Dodd ...

GeoVax Labs Inc. (GOVX), with a market capitalization of $12.2 million, reported its financial results for the full year 2024, revealing a net loss of $25 million, or $4.82 per share, on revenues of ...